| Literature DB >> 35883173 |
Masoumeh Rafiee1, Fariba Koohdani2, Faezeh Abaj3, Zahra Esmaeily3, Zeinab Naeini4.
Abstract
This investigation with aimed the effect of APOA2-265 T > C polymorphism and dietary acid load (DAL) as either potential renal acid load (PRAL) and net endogenous acid production (NEAP) intake interaction on metabolic markers in type 2 diabetes mellitus (T2DM). In present cross-sectional study, 737 patients with T2DM (290 men and 447 women) were enlisted from diabetes centers in Tehran. The dietary intakes of all participants during the last year was acquired by a validated semi-quantitative food frequency (FFQ) questionnaire. Polymerase chain reaction (PCR) was used for genotyping the APOA2-265 T > C. Biochemical indises containing leptin, ghrelin, total cholesterol (Bailey et al., J Clin Invest 97:1147-1453, 1996), low-density lipoprotein cholestrol (LDL-C), high-density lipoprotein cholestrol (HDL-C), triglyceride (TG), superoxide dismutase (SOD), high sensitivy C-reactive protein (hs-CRP), total antioxidant capacity (TAC), pentraxin-3 (PTX3), prostaglandin F2α (PGF2α) and interleukin 18 (IL18) were measured by standard method. Atherogenic indices (AIP, AC, CR-I, CR-II) were calculated. The gene-diet interactions were evaluated using an GLM. The frequency overall prevalence of rs5082 genotypes was 63.82 and 36.17% for T-allele and C-allele respectively. TG, Ghrelin, and hs-CRP concentrations were significantly higher among carriers with C allele than TT homozygotes. However, TC/CC genotypes have lower PTX3 than TT homozygotes (P < 0.05). C-allele carriers had highest mean of BMI (PNEAP=0.04, PPRAL = 0.006), WC (PNEAP=0.04, PPRAL = 0.04), TC (PNEAP=0.03, PPRAL = 0.01), ghrelin (PNEAP=0.01, PPRAL = 0.04), and leptin (PNEAP=0.04, PPRAL = 0.03) when placed in top tertiles of NEAP and PRAL.BMI, WC, TC, ghrelin, and leptin levels may be modified in C carriers by decreasing DAL, though, further investigations are required to confirm these findings.Entities:
Keywords: APOA2–265 T > C polymorphism; Dietary acid load; Nutrigenetic; T2DM
Mesh:
Substances:
Year: 2022 PMID: 35883173 PMCID: PMC9316730 DOI: 10.1186/s12902-022-01083-7
Source DB: PubMed Journal: BMC Endocr Disord ISSN: 1472-6823 Impact factor: 3.263
Comparison of the clinical characteristics according to APOA2 polymorphism
| APOA2–265 T > C | |||
|---|---|---|---|
| N | TT = 289 | (TC + CC) = 438 | |
| 53.78 ± 6.76 | 54.26 ± 6.49 | 0.33 | |
| 8 (33.3%) | 16 (66.7%) | 0.36 | |
| 53 (39.3%) | 82 (60.7%) | 0.24 | |
| 29.31 ± 4.65 | 29.39 ± 4.78 | 0.82 | |
| 92.19 ± 10.36 | 92.32 ± 10.72 | 0.86 | |
| 37.85 ± 5.54 | 37.74 ± 5.42 | 0.79 | |
| 2519.08 ± 844.92 | 2526.81 ± 938.86 | 0.91 | |
| 90.21 ± 34.16 | 90.33 ± 36.45 | 0.96 | |
| 339.53 ± 138.03 | 345.15 ± 145.92 | 0.59 | |
| 103.02 ± 46.72 | 103.76 ± 48.45 | 0.83 | |
| 1677.47 ± 620.64 | 1683.84 ± 605.14 | 0.88 | |
| 511.84 ± 227.72 | 508.27 ± 223.94 | 0.82 | |
| 4278.43 ± 1619.34 | 4343.19 ± 1732.50 | 0.6 | |
| 1153.31 ± 424.16 | 1168.80 ± 434.83 | 0.62 | |
| 2600.70 ± 282.01 | 2572.46 ± 275.94 | 0.41 | |
| 2020.54 ± 181.43 | 2022.1028 ± 183.50 | 0.93 | |
| −9.01 ± 0.26 | −9.03 ± 0.24 | 0.26 | |
| −10.89 ± 21.37 | −11.43 ± 22.54 | 0.74 | |
| 203.45 ± 70.5 | 196.04 ± 72.29 | 0.21 | |
| 52.67 ± 11.02 | 53.77 ± 13.72 | 0.52 | |
| 111.6 ± 34.64 | 109.61 ± 76.36 | 0.70 | |
| 184.89 ± 104.70 | 185.43 ± 109.28 | ||
| 2.16 ± 0.83 | 2.44 ± 1.48 | ||
| 24.51 ± 14.04 | 25.18 ± 14.71 | 0.73 | |
| 1.82 ± 1.23 | 2.48 ± 1.58 | ||
| 2.51 ± 0.56 | 2.45 ± 0.56 | 0.53 | |
| 0.14 ± 0.04 | 0.14 ± 0.04 | 0.29 | |
| 247.68 ± 33.83 | 249.36 ± 29.16 | 0.73 | |
| 71.60 ± 5.92 | 73 ± 6.19 | 0.16 | |
| 2.81 ± 0.45 | 2.52 ± 0.46 | ||
| 0.49 ± 0.24 | 0.48 ± 0.24 | 0.87 | |
| 3 ± 1.6 | 2.85 ± 1.77 | 0.23 | |
| 2.08 ± 0.65 | 2.07 ± 0.67 | 0.93 | |
| 4 ± 1.6 | 3.85 ± 1.77 | 0.23 | |
Values are means ± SD Independent T. test (Pvalue*). BMI Body mass index, WC Waist circumference, EER Estimated Energy Requirement, TG Triglyceride, TC Total cholesterol, hs-CRP High sensivity c-reactive protein, TAC Total antioxidant capacity, SOD Superoxide Dismutase, IL18 Interleukin 18, PGF2α Prostaglandin F2α. Atherogenic Index of Plasma (AIP) = log (TG/HDL-C), Atherogenic Coefficient (AC) = (TC-HDL-C)/HDL-C, Castelli’s Risk Index II (CRI-II) = (LDL/HDL), Castelli’s Risk Index I (CRI-I) = (TC/HDL-C)
The association between metabolic markers with NEAP and PRAL in T2DM patients
| Tertile of NEAP | Tertile of PRAL | |||||||
|---|---|---|---|---|---|---|---|---|
| T1 | T2 | T3 | T1 | T2 | T3 | |||
| 54.38 ± 6.29 | 53.77 ± 6.56 | 54.09 ± 6.89 | 0.59 | 54.45 ± 5.93 | 53.51 ± 6.97 | 54.26 ± 6.84 | 0.25 | |
| 29.39 ± 5.01 | 29.13 ± 4.44 | 29.53 ± 4.74 | 0.64 | 29.29 ± 4.67 | 29.32 ± 4.97 | 29.47 ± 4.55 | 0.90 | |
| 92.05 ± 11.27 | 91.60 ± 9.88 | 93.13 ± 10.54 | 0.26 | 91.47 ± 10.57 | 92.05 ± 10.80 | 93.29 ± 10.32 | 0.15 | |
| 38.09 ± 5.08 | 38.09 ± 5.58 | 37.14 ± 5.70 | 0.08 | 38.81 ± 5.7 | 37.27 ± 4.91 | 37.28 ± 5.62 | ||
| 2403.72 ± 823.39 | 2457.27 ± 736.39 | 2710.80 ± 1084.58 | 2622.06 ± 876.52 | 2271.40 ± 693.04 | 2679.12 ± 1051.77 | |||
| 2548.14 ± 276.67 | 2553.32 ± 258.79 | 2635.04 ± 290.23 | 2553.65 ± 279.22 | 2552.15 ± 253.93 | 2631.33 ± 291.47 | 0.06 | ||
| 2010.66 ± 189.44 | 2016.83 ± 161.13 | 2038.14 ± 193.95 | 0.41 | 2008.6 ± 175.19 | 2018.46 ± 176.05 | 2040.61 ± 197.73 | 0.32 | |
| 54.76 ± 13.44 | 52.35 ± 12.59 | 52.68 ± 11.73 | 0.07 | 55.45 ± 13.81 | 51.59 ± 11.86 | 52.76 ± 11.86 | ||
| 110.18 ± 37.86 | 106.72 ± 35.41 | 105.96 ± 32.16 | 0.37 | 111.14 ± 39.10 | 105.39 ± 33.97 | 106.89 ± 32.88 | 0.18 | |
| 195.70 ± 68.43 | 203.88 ± 75.79 | 197.76 ± 77.63 | 0.45 | 197.38 ± 70.67 | 200.93 ± 73.10 | 199.27 ± 78.34 | 0.87 | |
| 184.54 ± 107.98 | 185.52 ± 106.84 | 185.97 ± 108.05 | 0.98 | 190.78 ± 109.63 | 177.41 ± 100.91 | 187.39 ± 111.41 | 0.37 | |
| 25.76 ± 13.61 | 25.48 ± 14.75 | 23.16 ± 15.26 | 0.48 | 25.54 ± 13.52 | 25.38 ± 15.49 | 23.56 ± 14.55 | 0.65 | |
| 2.32 ± 1.02 | 2.32 ± 1.44 | 2.44 ± 1.47 | 0.83 | 2.16 ± 0.95 | 2.51 ± 1.45 | 2.42 ± 1.54 | 0.18 | |
| 2.31 ± 1.41 | 2.18 ± 1.59 | 2.24 ± 1.52 | 0.09 | 2.20 ± 1.41 | 2.28 ± 1.57 | 2.26 ± 1.52 | 0.96 | |
| 2.6 ± 0.48 | 2.66 ± 0.46 | 2.60 ± 0.49 | 0.72 | 2.56 ± 0.51 | 2.67 ± 0.44 | 2.61 ± 0.47 | 0.47 | |
| 250.74 ± 37.67 | 245.75 ± 26.09 | 250.69 ± 27.55 | 0.61 | 248.61 ± 37.47 | 247.30 ± 27.18 | 250.55 ± 28.07 | 0.84 | |
| 2.55 ± 0.53 | 2.45 ± 0.58 | 2.44 ± 0.56 | 0.54 | 2.61 ± 0.59 | 2.41 ± 0.52 | 2.42 ± 0.56 | 0.13 | |
| 0.14 ± 0.03 | 0.14 ± 0.04 | 0.15 ± 0.04 | 0.40 | 0.14 ± 0.03 | 0.13 ± 0.04 | 0.15 ± 0.04 | 0.34 | |
| 72.83 ± 6.05 | 73.25 ± 5.76 | 71.39 ± 6.56 | 0.25 | 72.80 ± 6.02 | 73.21 ± 5.85 | 71.46 ± 6.48 | 0.28 | |
| 0.48 ± 0.24 | 0.49 ± 0.25 | 0.49 ± 0.25 | 0.74 | 0.49 ± 0.23 | 0.48 ± 0.24 | 0.49 ± 0.26 | 0.98 | |
| 2.75 ± 1.59 | 3.07 ± 1.82 | 2.91 ± 1.70 | 0.13 | 2.75 ± 1.66 | 3.06 ± 1.74 | 2.93 ± 1.71 | 0.14 | |
| 2.06 ± 0.68 | 2.09 ± 0.67 | 2.06 ± 0.64 | 0.88 | 2.05 ± 0.7 | 2.09 ± 0.66 | 2.08 ± 0.64 | 0.85 | |
| 3.75 ± 1.59 | 4.07 ± 1.82 | 3.91 ± 1.70 | 0.13 | 3.75 ± 1.66 | 4.06 ± 1.74 | 3.93 ± 1.71 | 0.14 | |
Data are presented as mean ± standard deviation (SD). Abbreviation: PRAL Potential renal acid load, NEAP Net endogenous acid production, BMI Body mass index, WC Waist circumference, HDL-C High density lipoprotein cholesterol, LDL-C Low density lipoprotein cholesterol, CH Cholesterol, TG Triglyceride, hs-CRP High sensivity C-reactive protein, PTX3 Pentraxin 3, IL18 Interleukin 18, TAC Total antioxidant capacity, SOD Superoxide dismutase, PGF2α ProstaglandinF2α. Atherogenic Index of Plasma (AIP) = log (TG/HDL-C), Atherogenic Coefficient (AC) = (TC-HDL-C)/HDL-C, Castelli’s Risk Index II (CRI-II) = (LDL/HDL), Castelli’s Risk Index I (CRI-I) = (TC/HDL-C) a Obtained from ANOVA
Fig. 1Interaction effect between NEAP (mEq/d) and APOA2–256 (C > T) on a BMI, b WC, c TC, d Ghrelin, e Leptin. P 1 = P value with unadjusted (crude) model, P 2 = P value with adjustments for potential confounding factors including (age, physical activity, sex, smoking, alcohol, energy intake, alcohol, lipid and glucose-lowering medications). The lines indicate mean ± Error bar (SD). BMI: body mass index, WC: waist circumstance, TC: total cholesterol
Fig. 2Interaction effect between PRAL (mEq/d) and APOA2–256 (C > T) on a BMI, b WC, c TC, d Ghrelin, e Leptin. P 1 = P value with unadjusted (crude) model, P 2 = P value with adjustments for potential confounding factors including (age, physical activity, sex, smoking, alcohol, energy intake, alcohol, lipid and glucose-lowering medications). The lines indicate mean ± Error bar (SD). BMI: body mass index, WC: waist circumstance, TC: total cholesterol